Xigduo is a diabetes medicine used, together with diet and exercise in adults with type 2 diabetes. It contains the active substances dapagliflozin and metformin. Xigduo is used: - on its own in patients whose disease is not controlled well enough with metformin alone; - in combination with other diabetes medicines when these medicines together with metformin are not controlling the diabetes well enough. Xigduo can also be used to replace dapagliflozin and metformin taken as separate tablets.
Therapeutic Indication
### Therapeutic indication Xigduo is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise: • in patients insufficiently controlled on their maximally tolerated dose of metformin alone • in combination with other medicinal products for the treatment of diabetes in patients insufficiently controlled with metformin and these medicinal products • in patients already being treated with the combination of dapagliflozin and metformin as separate tablets. For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.
Therapeutic Area (MeSH)
ATC Code
A10BD15
ATC Item
metformin and dapagliflozin
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
EMA Name
Xigduo
Medicine Name
Xigduo
Aliases
N/ANo risk management plan link.
